Characteristics of 2 patients with complex karyotype including monosomy 7 achieving a cytogenetic and hematologic complete remission
| . | Patient 4003 . | Patient 4007 . |
|---|---|---|
| No. of DAC courses | 5 + 1 | 4 |
| Best response (no. of courses) | CR (4) | CR (2) |
| % bone marrow blasts, before treatment/best response | 25/<5 | 28/0 |
| % peripheral blood blasts, before treatment/best response | 0/0 | 18/0 |
| WBC, × 109/L, before treatment/best response | 2.3/7.6 | 20.2/3.6 |
| ANC, × 109/L, before treatment/best response | 0.5/4.6 | 4.4/1.9 |
| Hemoglobin, g/dL, before treatment/best response | 7.2/14.3 | 7.1/12.8 |
| Platelet, × 1012/L, before treatment/best response | 29/174 | 25/269 |
| Karyotype before treatment [no. of metaphases] | 43, XX, −2, del(5)(q13q33), −7, del(12)(q14q22), der(16), t(16;?)(q11;?), del(20)(q11), −22 [10] | 44, XX, −6, −7, 12q−, 18q+, t(12;18)(q13;q23) [13] |
| Karyotype at time of best response [no. of metaphases] | 46, XX [20] | 46, XX [20] |
| Response duration from first response, mo | 10 | 6.5 |
| Survival from treatment start, mo | 15 | 13 |
| Hospital nights from start of DAC | 93 | 73 |
| Hospital nights divided by days survival from start of DAC, % | 21 | 18 |
| . | Patient 4003 . | Patient 4007 . |
|---|---|---|
| No. of DAC courses | 5 + 1 | 4 |
| Best response (no. of courses) | CR (4) | CR (2) |
| % bone marrow blasts, before treatment/best response | 25/<5 | 28/0 |
| % peripheral blood blasts, before treatment/best response | 0/0 | 18/0 |
| WBC, × 109/L, before treatment/best response | 2.3/7.6 | 20.2/3.6 |
| ANC, × 109/L, before treatment/best response | 0.5/4.6 | 4.4/1.9 |
| Hemoglobin, g/dL, before treatment/best response | 7.2/14.3 | 7.1/12.8 |
| Platelet, × 1012/L, before treatment/best response | 29/174 | 25/269 |
| Karyotype before treatment [no. of metaphases] | 43, XX, −2, del(5)(q13q33), −7, del(12)(q14q22), der(16), t(16;?)(q11;?), del(20)(q11), −22 [10] | 44, XX, −6, −7, 12q−, 18q+, t(12;18)(q13;q23) [13] |
| Karyotype at time of best response [no. of metaphases] | 46, XX [20] | 46, XX [20] |
| Response duration from first response, mo | 10 | 6.5 |
| Survival from treatment start, mo | 15 | 13 |
| Hospital nights from start of DAC | 93 | 73 |
| Hospital nights divided by days survival from start of DAC, % | 21 | 18 |
DAC indicates decitabine; CR, complete remission; WBC, white blood cells; ANC, absolute neutrophil count.